Vinflunine: A new microtubule inhibitor agent

被引：72
作者：
Bennouna, Jaafar [1 ]
Delord, Jean-Pierre [2 ]
Campone, Mario [1 ]
Nguyen, Laurent [3 ]
机构：
[1] Ctr Rene Gauducheau, F-44805 St Herblain, France
[2] Inst Claudius Regaud, Toulouse, France
[3] Inst Rech Pierre Fabre, Boulogne, France
来源：
CLINICAL CANCER RESEARCH | 2008年 / 14卷 / 06期
关键词：
D O I：
10.1158/1078-0432.CCR-07-2219
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Vinflunine (Javlor) is the first fluorinated microtubule inhibitor belonging to the Vinca alkaloids family. Vinflunine is obtained by semisynthesis using superacidic chemistry to selectively introduce two fluorine atoms at the 20' position of the catharanthine moiety. This compound has been selected for clinical development on the basis of encouraging preclinical activity that warrants study in patients with a wide spectrum of solid tumors. Clinically significant activity has been seen in phase 11 studies, mainly in the treatment of transitional cell carcinoma of the urothelial tract, non-small cell lung cancer, and carcinoma of the breast. Vinflunine is currently in phase III trial assessment in patients with (second line) transitional cell carcinoma of the urothelium and first-line advanced breast cancer. The efficacy of vinflunine in patients with advanced non-small cell lung cancer previously treated with a platinum-containing regimen was confirmed by a large phase III trial.
引用
收藏
页码：1625 / 1632
页数：8
相关论文
共 47 条
[1]   In vitro synergistic effects of vinflunine, a novel fluorinated vinca alkaloid, in combination with other anticancer drugs [J].
Barret, JM ;
Etiévant, C ;
Hill, BT .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2000, 45 (06) :471-476
[2]   Vinflunine - an active chemotherapy for treatment of advanced non-small-cell lung cancer previously treated with a platinum-based regimen: results of a phase II study [J].
Bennouna, J. ;
Breton, J. -L. ;
Tourani, J. -M. ;
Ottensmeier, C. ;
O'Brien, M. ;
Kosmidis, P. ;
Huat, T. E. ;
Pinel, M. -C. ;
Colin, C. ;
Douillard, J. -Y .
BRITISH JOURNAL OF CANCER, 2006, 94 (10) :1383-1388
[3]   Vinflunine: a novel antitubulin agent in solid malignancies [J].
Bennouna, J ;
Campone, M ;
Delord, JP ;
Pinel, MC .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2005, 14 (10) :1259-1267
[4]   Phase I and pharmacokientic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours [J].
Bennouna, J ;
Fumoleau, P ;
Armand, JP ;
Raymond, E ;
Campone, M ;
Delgado, FM ;
Puozzo, C ;
Marty, A .
ANNALS OF ONCOLOGY, 2003, 14 (04) :630-637
[5]   Higher antitumor activity of vinflunine than vinorelbine against an orthotopic murine model of transitional cell carcinoma of the bladder [J].
Bonfil, RD ;
Russo, DM ;
Binda, MM ;
Delgado, FM ;
Vincenti, M .
UROLOGIC ONCOLOGY, 2002, 7 (04) :159-166
[6]  
Campone M, 2006, BREAST CANCER RES TR, V100, pS279
[7]   Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane-based chemotherapy [J].
Campone, M. ;
Cortes-Funes, H. ;
Vorobiof, D. ;
Martin, M. ;
Slabber, C. F. ;
Ciruelos, E. ;
Bourbouloux, E. ;
Mendiola, C. ;
Delgado, F. M. ;
Colin, C. ;
Aslanis, V. ;
Fumoleau, P. .
BRITISH JOURNAL OF CANCER, 2006, 95 (09) :1161-1166
[8]   Current status and future prospects for satraplatin, an oral platinum analogue [J].
Choy, Hak ;
Park, Clinton ;
Yao, Min .
CLINICAL CANCER RESEARCH, 2008, 14 (06) :1633-1638
[9]   A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen [J].
Culine, S. ;
Theodore, C. ;
De Santis, M. ;
Bui, B. ;
Demkow, T. ;
Lorenz, J. ;
Rolland, F. ;
Delgado, F. -M. ;
Longerey, B. ;
James, N. .
BRITISH JOURNAL OF CANCER, 2006, 94 (10) :1395-1401
[10]   Bcl-2 down-regulation and tubulin subtype composition are involved in resistance of ovarian cancer cells to vinflunine [J].
Esteve, Marie-Anne ;
Carre, Manon ;
Bourgarel-Rey, Veronique ;
Kruczynski, Anna ;
Raspaglio, Giuseppina ;
Ferlini, Cristiano ;
Braguer, Diane .
MOLECULAR CANCER THERAPEUTICS, 2006, 5 (11) :2824-2833
12345